Comparison of the biological principles underlying the action of monoclonal antibody (mAb) and decoy receptor anti-VEGF agents – on the example of ranibizumab (anti-VEGF-A mAb) and aflibercept (decoy VEGFR1-2 receptor)

Paweł Golik; Katarzyna Tońska

Full text

1/2012 vol. 114

Review paper

Comparison of the biological principles underlying the action of monoclonal antibody (mAb) and decoy receptor anti-VEGF agents – on the example of ranibizumab (anti-VEGF-A mAb) and aflibercept (decoy VEGFR1-2 receptor)

Paweł Golik ¹

,

Katarzyna Tońska ¹

Instytut Genetyki i Biotechnologii Wydziału Biologii Uniwersytetu Warszawskiego

Klinika Oczna 2012, 114 (1)

Data publikacji online: 2012/03/29

Article file

17 GOLIK_POROWNANIE.pdf

AMA

Golik P, Tońska K. Comparison of the biological principles underlying the action of monoclonal antibody (mAb) and decoy receptor anti-VEGF agents – on the example of ranibizumab (anti-VEGF-A mAb) and aflibercept (decoy VEGFR1-2 receptor). Klinika Oczna / Acta Ophthalmologica Polonica. 2012;114(1):79-83.

APA

Golik, P., & Tońska, K. (2012). Comparison of the biological principles underlying the action of monoclonal antibody (mAb) and decoy receptor anti-VEGF agents – on the example of ranibizumab (anti-VEGF-A mAb) and aflibercept (decoy VEGFR1-2 receptor). Klinika Oczna / Acta Ophthalmologica Polonica, 114(1), 79-83.

Chicago

Golik, Paweł, and Katarzyna Tońska. 2012. "Comparison of the biological principles underlying the action of monoclonal antibody (mAb) and decoy receptor anti-VEGF agents – on the example of ranibizumab (anti-VEGF-A mAb) and aflibercept (decoy VEGFR1-2 receptor)". Klinika Oczna / Acta Ophthalmologica Polonica 114 (1): 79-83.

Harvard

Golik, P., and Tońska, K. (2012). Comparison of the biological principles underlying the action of monoclonal antibody (mAb) and decoy receptor anti-VEGF agents – on the example of ranibizumab (anti-VEGF-A mAb) and aflibercept (decoy VEGFR1-2 receptor). Klinika Oczna / Acta Ophthalmologica Polonica, 114(1), pp.79-83.

MLA

Golik, Paweł et al. "Comparison of the biological principles underlying the action of monoclonal antibody (mAb) and decoy receptor anti-VEGF agents – on the example of ranibizumab (anti-VEGF-A mAb) and aflibercept (decoy VEGFR1-2 receptor)." Klinika Oczna / Acta Ophthalmologica Polonica, vol. 114, no. 1, 2012, pp. 79-83.

Vancouver

Golik P, Tońska K. Comparison of the biological principles underlying the action of monoclonal antibody (mAb) and decoy receptor anti-VEGF agents – on the example of ranibizumab (anti-VEGF-A mAb) and aflibercept (decoy VEGFR1-2 receptor). Klinika Oczna / Acta Ophthalmologica Polonica. 2012;114(1):79-83.

SUBMIT YOUR PAPER

Share

Integrated with

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications